Oliver Luxxe Assets LLC Buys Shares of 8,787 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Oliver Luxxe Assets LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,787 shares of the medical equipment provider’s stock, valued at approximately $547,000.

Other institutional investors also recently bought and sold shares of the company. City State Bank raised its stake in shares of Lantheus by 44.6% in the first quarter. City State Bank now owns 1,945 shares of the medical equipment provider’s stock worth $121,000 after buying an additional 600 shares during the period. Silverberg Bernstein Capital Management LLC raised its stake in shares of Lantheus by 1.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 22,743 shares of the medical equipment provider’s stock worth $1,416,000 after buying an additional 400 shares during the period. Private Capital Management LLC raised its stake in shares of Lantheus by 27.9% in the fourth quarter. Private Capital Management LLC now owns 556,771 shares of the medical equipment provider’s stock worth $34,520,000 after buying an additional 121,290 shares during the period. Clearview Wealth Advisors LLC bought a new position in shares of Lantheus in the first quarter worth about $342,000. Finally, Juncture Wealth Strategies LLC bought a new position in shares of Lantheus in the first quarter worth about $382,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LNTH shares. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Truist Financial raised their price objective on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Finally, B. Riley lifted their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.17.

Lantheus Stock Down 0.4 %

Shares of LNTH opened at $80.00 on Tuesday. The business’s 50 day moving average is $77.75 and its 200 day moving average is $65.94. The company has a market capitalization of $5.54 billion, a PE ratio of 12.21 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $91.81. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.11. The business had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. Research analysts expect that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the completion of the transaction, the director now owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The disclosure for this sale can be found here. Insiders sold 32,269 shares of company stock worth $2,557,300 in the last quarter. 2.10% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.